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INTRODUCTION 
The establishment of tissue-specific gene expression pro-
files relies on a variety of transcription factor cascades, which
initiate embryogenesis and development, and on DNA methy-
lation, which prevents the reactivation of inactive genes (1).
The promoter regions of the housekeeping genes always over-
lap with the CpG islands, whereas approximately 60% of the
genes lacking CpG islands are expressed in a tissue-specific
manner (2, 3). However, an inverse correlation between the
methylation state and gene expression is found in only 30%
of the genes randomly selected (4). Therefore, it is believed
that rather than simply acting as an on-off switch in gene reg-
ulation, DNA methylation is essential for maintaining the
well-organized gene expression in a variety of somatic tissues
(5), and that changes in the normal methylation state might
play a role in the genesis and development of cancers (6).
The loss-of-heterozygosity (LOH) event detected by an
analysis of microsatellite sequences represents the unilateral
chromosomal loss, major genetic alterations observed in human
solid tumors (7). Although the LOH event may be a part of
bi-allelic gene inactivation, it is still unclear if a decrease in
the chromosomal dose plays a role in carcinogenesis. Assum-
ing the DNA methylation profile of a given tissue is estab-
lished with respect to the global gene expression profiles, it
is possible that the gene-copy number reduction caused by
LOH can influence the methylation and transcriptional sta-
tus of the genes on the chromosomal copies retained. How-
ever, there are a few reports describing the functional rela-
tionship between the genetic and epigenetic features of can-
cer cells, especially on how the LOH events and methylation
changes collectively influence the global gene expression pro-
files of cancer cells. We previously observed that the methy-
lation-variable CpG sites between unmethylated promoters
and nearby methylated retroelements, including the CpG-
island margins and the non-island-CpG sites the genes lack-
ing CpG islands, are associated with the global as well as
individual gene expression patterns (8-10). These findings
lead us to propose an assumption that a decrease in the num-
ber of active gene copy caused by LOH might facilitate the
methylation changes in the transitional-CpG sites as well as
the changes in the total number of active genes.
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Chromosomal Losses are Associated with Hypomethylation of the
Gene-Control Regions in the Stomach with a Low Number of Active
Genes
Transitional-CpG methylation between unmethylated promoters and nearby methy-
lated retroelements plays a role in the establishment of tissue-specific transcription.
This study examined whether chromosomal losses reducing the active genes in
cancers can change transitional-CpG methylation and the transcription activity in a
cancer-type-dependent manner. The transitional-CpG sites at the CpG-island mar-
gins of nine genes and the non-island-CpG sites round the transcription start sites
of six genes lacking CpG islands were examined by methylation-specific polymerase
chain reaction (PCR) analysis. The number of active genes in normal and cancer-
ous tissues of the stomach, colon, breast, and nasopharynx were analyzed using
the public data in silico. The CpG-island margins and non-island CpG sites tended
to be hypermethylated and hypomethylated in all cancer types, respectively. The
CpG-island margins were hypermethylated and a low number of genes were active
in the normal stomach compared with other normal tissues. In gastric cancers, the
CpG-island margins and non-island-CpG sites were hypomethylated in associa-
tion with high-level chromosomal losses, and the number of active genes increased.
Colon, breast, and nasopharyngeal cancers showed no significant association
between the chromosomal losses and methylation changes. These findings sug-
gest that chromosomal losses in gastric cancers are associated with the hypomethy-
lation of the gene-control regions and the increased number of active genes.
Key Words : Chromosomal Loss; Loss of Heterozygosity; CpG Methylation; Methylation-Specific PCR; Tissue
Expression Profiles
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In this study, we examined the chromosomal losses events,
methylation changes, and global expression profiles in gas-
tric, colonic, mammary and nasopharyngeal cancers in order
to further delineate the interaction of genetic, epigenetic,
and transcriptional alterations using LOH, methylation-spe-
cific polymerase chain reaction (PCR) and Serial Analysis of
Gene Expression (SAGE) data. 
MATERIALS AND METHODS
Collection of cancer and normal tissues
Formalin-fixed, paraffin-embedded tissue sections of four
cancer types (stomach, colon, breast, and nasopharynx) were
obtained from 100 patients who had undergone a surgical
resection between March 2004 and July 2006 at St. Paul’s
Hospital and Kangnam St. Mary’s Hospital, The Catholic
University of Korea. The Institutional Review Board approved
this study, and written informed consent was obtained from
each patient before surgery. A single 10-mm-diameter site
containing a homogeneous cell population was selected from
each section that contained a representative of paired normal
and tumor tissues. Seven-μ m-thick hematoxylin-eosin-stained
sections were microdissected under a 40× stereomicroscope
using a surgical scalpel. In the microscopic examination, the
tumor specimens consisted mainly of tumor tissue and the
normal tissues did not show any evidence of tumor cell inva-
sion or significant inflammatory involvement. Approximate-
ly 50 microdissected cells were digested in 1 μ L of a Tween
20-Proteinase K lysis buffer. 
PCR-based microsatellite analysis
A pair of normal and cancer DNAs was examined using a
panel of PCR primers that covered 40 microsatellite loci on
eight cancer-associated chromosomes, 3p, 4p, 5q, 8p, 9p, 13q,
17p, and 18q, as reported elsewhere (11-14). The allelic pro-
files of the 40 microsatellite sequences were initially analyzed
for any microsatellite instability (MSI) at the homozygous mark-
ers showing a few stutter bands in a pair of normal and cancer
tissues. If the cancer DNA showed novel bands that were
absent in normal DNA, in >40% of the homozygous mic-
rosatellite alleles, they were interpreted as being a MSI. The
difference in the allelic intensity between the normal and
cancer DNAs was scored as the relative allelic ratio calculat-
ed by dividing the intensity ratio of the cancer by the nor-
mal allelic ratio. A relative allelic ratio >1.5 in the heterozy-
gous case without a MSI was interpreted as a LOH on the
basis of the distribution of relative allelic ratios, as this pro-
vided the best discrimination between wild-type heterozy-
gosity and LOH.
Methylation-specific PCR and sequencing of bisulfite-
modified DNA 
Ninety microliters of genomic DNA was denatured with
10 μ L of 3 M NaOH for 15 min at 37℃ and modified with
1,040 μ L of 2.3 M sodium bisulfite and 60 μ L of 10 mM
hydroquinone for 12 hr at 50℃, as described elsewhere (12,
13). The methylation-variable CpG sites reported in previ-
ous study of 11 somatic tissue types were chosen in the tran-
sitional area between promoters and retroelements (9). A total
of 15 CpG sites selected from six CpG-island-negative genes
(MAGEA2,TFF2,DDX53,MSLN,MASPIN, and BGLAP)
and nine CpG-island-positive genes (MUC8, KIAA1752,
CDKN2A, ESR2, PPARG, MLH1, CDH1, VDR, and
RUNX3) were examined using methylation-specific PCR
(MSP) primer sets (Supplementary Table 1 and 2). Supple-
mentary Fig. 1 shows the coverage of CpG islands along with
The mean numbers of active genes and the expressed tags were calculated using two to eight SAGE libraries for each tissue type. Individual genes
were classified according to on the presence or absence of CpG islands and the type of nearby retroelements in the 5′ -end regions.
Genes with CpG islands
Alu and L1 retroelement
Active 
genes
Tags per
gene
L1 retroelement
Tissue
Active 
genes
Tags per
gene
Alu retroelement
Active 
genes
Tags per
gene
L1 retroelement
Active 
genes
Tags per
gene
Alu retroelement
Active 
genes
Tags per
gene
Genes without CpG islands
Embryo 513 7.1 3,576  15.3 5,817  16.7  999  5.7  810  6.7 
Placenta 395 4.6 2,885 7.8 4,652 8.1  870 10.3  704  11.9 
Normal tissues
Stomach 213 2.3 1,676 4.3 2,636 4.2 444 11.4 368 5.0 
Colon 246 3.9 2,108 5.0 3,529 5.1  543  7.3  480  3.8 
Breast 332 3.5 2,386 5.6 3,988 5.9 672 4.6 543  5.2 
Cancer tissues
Stomach 315 3.0 2,273 5.7 3,736 6.0 624 4.8 540 5.5 
Colon 289 2.5 2,382 4.2 3,910 4.5 643 4.0 541 3.0 
Breast 334 3.1 2,474 5.4 4,122 5.9  641  3.9  552 4.0 
Table 1. The number of active genes and the number of tags expressed per active gene in embryos and somatic tissues1070 Y.-C. Jung, S.-J. Hong, Y.-H. Kim, et al.
the distribution of retroelements in the 5′ -end regions of
the 15 genes examined.
For semiquantitative MSP analysis, a minimum number
of PCR rounds to reach sub-plateau DNA amplification were
performed using a radioisotope. The bisulfite-modified DNA
was amplified and labeled by a hot-start PCR containing α -32P
dTTP (PerkinElmer, Boston, MA, U.S.A.) and dNTP mix-
ture through 32 PCR cycles. The PCR products were load-
ed onto a nondenaturing polyacrylamide gel and visualized
by repeated autoradiography using a radioluminograph scan-
ner (BAS 2500, Fuji Photo Film, Kanakawa, Japan) and ana-
lyzed with TINA image software (Raytest Isotopenmeβ ger-
ate, Straubenhardt, Germany). The specificity of each MSP
primer set was validated using a standard curve for the uni-
versal methylated and unmethylated DNAs, as described
elsewhere (9).
The relative proportion of the methylated CpG band to
the total intensity of the methylated and unmethylated CpG
bands was calculated from the MSP bands amplified by the
MSP primer set. The proportion of methylated CpGs was
divided into 5 levels; level 1 (0-20% methylation), level 2
(21-40% methylation), level 3 (41-60% methylation), level
4 (61-80% methylation), and level 5 (81-100% methyla-
tion). The results of the LOH and MSP analyses on the four
cancer types are listed in Supplementary Table 3.
The methylation-variable CpGs of the TFF2, MSLN,
BGLAP, CDKN2A, and MLH1 genes were analyzed by
cloning and sequencing of the common PCR DNA (Sup-
plementary Fig. 2). The common PCR primer sets were
designed to span both the unmethylated and methylated
CpGs in the CpG amplicons. The PCR product of each com-
mon primer set was cloned into the T&A cloning vector
(Real Biotech, Taipei, Taiwan). The DNA sequencing was
performed using a BigDye Terminator Kit (PE Biosystems,
Genes with CpG islands
L1 element
Embryo Placenta
Alu and L1
Embryo Placenta
Alu element
Embryo Placenta
L1 element
Embryo Placenta
Alu element
Embryo Placenta
Genes without CpG islands
Normal tissues
Stomach 1 0.48 0.16 0.33 0.59 0.44 0.45 0.05 0.01  0.20 0.10 
2 0.39 0.17  0.31  0.59 0.51 0.54 0.04 0.02  0.21 0.07 
3 0.57  0.27 0.48 0.72 0.63 0.81 0.09 0.03 0.17 0.11 
4 0.47 0.42 0.50 0.73 0.47  0.54 0.10  0.27 0.20 0.12
Colon 1 0.34  0.10  0.20 0.43 0.20 0.32  0.33 0.14 0.02 0.05 
2 0.62 0.07  0.24 0.48 0.27 0.35  0.22 0.06 0.07 0.13
Breast 1 0.08  0.32  0.69 0.59 0.68 0.75  0.73 0.20 0.05 0.01 
2 0.15 0.19 0.55  0.44  0.63 0.70 0.61 0.17 0.06 0.01 
3 0.11  0.36 0.57  0.46  0.70 0.70 0.51 0.19 0.25 0.39
4 0.17 0.34 0.61 0.58 0.61 0.66 0.57 0.21 0.19 0.90
5 0.11  0.30 0.61  0.45  0.70 0.67 0.39 0.10 0.31 0.18
6 0.15 0.24 0.64 0.51 0.75 0.56  0.64 0.21 0.24 0.08 
Cancer tissues
Stomach 1 0.26 0.17 0.68 0.78 0.53 0.66  0.68 0.15 0.29 0.19
2 0.28 0.35  0.66 0.57 0.53 0.70  0.55 0.21 0.17 0.79
3 0.21 0.21 0.65 0.58 0.50 0.64 0.41 0.14 0.20 0.75
4 0.25 0.26 0.59 0.57 0.68 0.50  0.64 0.12 0.12 0.25
5 0.33 0.30 0.63 0.79 0.54 0.60 0.66 0.22 0.38 0.53
6 0.31 0.37 0.66 0.83 0.72 0.73  0.73 0.18 0.32 0.78 
Colon 1 0.45  0.12  0.29  0.50  0.37  0.54 0.55 0.29  0.09 0.02 
2 0.29  0.13  0.38 0.35 0.24 0.46  0.44 0.14 0.35 0.28 
Breast 1 0.34  0.50 0.65 0.78 0.46  0.55 0.54 0.17 0.21 0.51 
2 0.19 0.37 0.60 0.77 0.56 0.53  0.56 0.18 0.28 0.58
3 0.14  0.13  0.70 0.51 0.63 0.45  0.56 0.08  0.30  0.07 
4 0.34 0.20 0.69 0.72 0.72 0.67 0.59 0.48 0.09 0.01 
5 0.17 0.28 0.70 0.63 0.57 0.73  0.39 0.08  0.31 0.18 
6 0.33 0.42 0.64 0.76 0.47  0.54  0.46 0.13 0.18 0.56
7 0.18 0.35 0.61 0.72 0.40 0.44  0.62  0.18 0.20 0.31 
8 0.40 0.18 0.70 0.73 0.58 0.67  0.54 0.13 0.32 0.82
Table 2. Statistical analysis (R values) of the number of expressed tags for gene expression similarities between the embryo and somat-
ic tissues
Using the SAGE data in silico, the number of expressed tags of individual genes was compared between the embryo (embryonic cell line of passage
16 and the first trimester placenta) and somatic tissues. Total genes were classified according to the presence or absence of CpG islands and the
type of the nearby retroelements. Pearson’s correlation coefficients of p<0.05 are marked in bold. R values ≥0.5 are indicated by italics. Genetic and Epigenetic Changes Related with Transcript Number in Gastric Cancer 1071
Foster City, CA, U.S.A.) and an ABI automated DNA se-
quencer (PE Biosystems, Warrington, U.K.). The intensity
of the MSP bands was compared with the distribution of
methylated CpGs, which were determined by cloning and
sequencing of the common PCR amplicons.
Methylation analysis of normal somatic tissues
The methylation status of the transitional CpGs examined
in 11 normal somatic tissues was previously reported (9).
This study extended the previous data by adding six transi-
tional sites (TFF2, MSLN, BGLAP, MUC8, KIAA1752,
and PPARG) and three somatic tissues (fat, ovary, and testis).
A total of eleven tissue types were collected from 51 indi-
viduals. The bone marrow and fat stromal cells were obtained
from three individuals (10) and each of the remaining nine
tissue types were obtained from five individuals. The stom-
ach and colon was divided into proximal and distal portions
according to the anatomic landmarks, gastric body and the
splenic flexure of the colon.
Analysis of in-silico data
A total of 32 SAGE libraries for the embryonic stem cells,
placenta, stomach, colon, and breast tissues were obtained
from a public database (http://cgap.nci.nih.gov/SAGE/). Six
expressed sequence tag (EST) libraries for the nasopharyn-
geal tissues were collected from a public database (http://cgap.
nci.nih.gov/Tissues) because of no SAGE data available. The
SAGE and EST libraries analyzed are listed in Supplemen-
tary Table 4. The SAGE tags and EST tags were assigned
using UniGene cluster ID by accumulating the total expressed
tags to the matched genes at each tissue library. A total of
434,325 expressed tags in the 32 SAGE libraries correspond-
ed to the 15,770 gene symbols through tag-to-gene matching.
The genomic location of the NCBI RefSeq cDNA sequ-
A
17p 18q 9p 13q 5q 4p 3p 8p
Individual chromosomal loss
Gastric cancer
Fig. 1. Chromosomal losses detected in the gastric, colonic, mammary, and nasopharyngeal cancers (25 cases for each cancer type).
(A) Individual chromosomal losses and (B) the number of chromosomal losses were evaluated by PCR-based analysis using 40 microsatel-
lite markers on chromosomes 3p, 4p, 5q, 8p, 9p, 13q, 17p, and 18q.
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The methylation of the CpG-island margins were divided into four levels (+, ++, +++, and ++++) according to the genome-wide DNA methylation of
the embryo (27, 28) and the placenta (29) and the CpG-island margin methylation estimated in somatic tissues (Fig. 4). The number of active genes
and the transcript number per active gene were divided into four or five levels according to the ranks observed in the embryo and somatic tissues
(Fig. 5). Hypomethylation changes in cancer tissues are detailed in Fig. 3. NE, not examined.
Nasopharynx Breast Colon Stomach Placenta Embryo
CpG-island margin methylation + ++ ++++ ++++ +++ +++
Association between high-level LOH  NE NE Yes No No No
and hypomethylation
Genes with CpG islands
No. of active genes +++++ ++++ + ++ +++ NE
Transcript number per gene +++++ ++++ + ++ +++ NE
Genes without CpG islands
No. of active genes +++++ ++++ + ++ +++ NE
Transcript number per gene ++ ++++ +++ ++ + NE
L1-close transcript proportion + +++ ++++ +++ ++ ++
Table 3. The methylation status of CpG-island margins, the number of active genes, and the transcript number per active gene in
embryo and somatic tissues1072 Y.-C. Jung, S.-J. Hong, Y.-H. Kim, et al.
ences was obtained from the genome web site (UCSC Gold-
en Path May, 2004 assembly, http://genome.ucsc.edu/). A
3-kb sized non-overlapping window was used to analyze a
DNA segment upstream and downstream of the transcrip-
tion start site. The coverage of CpG islands and the distri-
bution of retroelements compiled from searches of the genome
database were evaluated by inputting the sequence data that
was delimited from the 5′ -end regions into a local program.
The annotation of retroelements was made using the Repeat-
Masker program (http://ftp.genome.washington.edu/RM/
RepeatMasker.html). A total of 15,770 active genes show-
ing the tag-and-gene match were demarcated by the pres-
ence or absence of CpG islands at the transcription sites as
well as the types of nearby retroelements existing in a 3-kb
window. For the fidelity of the genome-wide expression data,
we compared SAGE and Affymetrix GeneChip (http://sy-
matlas.gnf.org/SymAtlas), and there was strong agreement
in major mRNA content of the analyzed tissue types (data
not shown) as previous reports (15, 16). However, the SAGE
data was found to reliably reflect the wide-range of transcrip-
tion level by counting the sequence-based ‘digital’ tags, while
the microarray data based on the fluorescence signal was not
suitable for defining the active or inactive transcription sta-
tus as well as the estimation of strong transcription activi-
ties due to the limit of probe hybridization method. 
Statistical analysis
A chi-square test was used to compare the methylation
changes between gastric, colonic, mammary, and nasopha-
ryngeal cancers. The Pearson’s correlation coefficients of the
expressed tag numbers in different tissues were calculated to
determine the similarities of the individual gene expression.
A two-sided pvalue <0.05 was considered significant.
RESULTS
The level of chromosomal losses estimated in four cancer
types
The LOH events in each cancer were determined using 40
MAGEA2
Fig. 2. Methylation changes in the transitional-CpG sites of the 15 selected genes examined in four cancer types. The methylation status
of the transitional-CpG sites was estimated using a semiquantitative methylation-specific PCR method. The methylation changes were
scored based on the difference in the level of methylation between the normal and tumor tissues. The frequency of methylation changes
in each transitional area is indicated as a percentage in 25 cancer cases. The level of chromosomal losses was evaluated by PCR-based
loss-of-heterozygosity analysis. The cancer tissues were grouped into high-level chromosomal losses (H) four or more chromosomes and
low-level chromosomal losses (L) involving less than four chromosomes. 
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microsatellite markers on eight cancer-associated chromo-
somes. In order to count the substantial loss of a chromo-
some, a unilateral chromosomal loss was defined when two
or more allelic losses were detected on a single chromosome
in cancer tissue. Fig. 1 shows the frequency of individual
chromosomal losses and the number of chromosomal losses
examined in four cancer types. The losses of chromosomes
17p and 18q were most frequent in gastric (72% and 68%)
and colonic cancers (64% and 56%). An 8p loss was most
common in mammary cancers (60%) and 9p loss (72%) most
frequent in nasopharyngeal cancers. The level of LOH was
categorized as high level (involving four or more chromo-
somes) and low level (involving less than four chromosomes).
High- and low-level chromosomal losses had a similar fre-
quency in gastric (56% vs. 44%) and colonic (48% vs. 52%)
cancers. Mammary and nasopharyngeal cancers frequently
showed low-level (64%) and high-level (72%) chromoso-
mal losses, respectively. 
Methylation changes in the transitional-CpG sites
A total of 15 transitional-CpG sites selected from six CpG-
island-negative genes (MAGEA2, TFF2, DDX53, MSLN,
MASPIN, and BGLAP) and nine CpG-island-positive genes
(MUC8, KIAA1752, CDKN2A, ESR2, PPARG, MLH1,
CDH1, VDR, and RUNX3) were examined using MSP
primer sets (Supplementary Fig. 1, Supplementary Table 1-
3). The methylation density of the CpG amplicon was divid-
ed into the following 5 levels: 1 (0-20%), 2 (21-40%), 3
(41-60%), 4 (61-80%), and 5 (81-100%). The frequency of
the methylation changes was scored as the number of the
CpG amplicons showing a difference in the level of methyla-
tion between the normal and tumor DNAs.
Fig. 2 shows the methylation status of the transitional-CpG
sites examined in the four cancer types. The non-island CpG
sites round the transcription start sites of the MAGEA2,
TFF2, and DDX53 genes lacking CpG islands were hy-
pomethylated at various frequencies (16-48%). The CpG-
island margins of the VDR, MLH1, and RUNX3 genes
bordered by retroelements at a long distance had a tendency
for hypermethylation in various frequencies (16-76%). A
total of 1,500 CpG amplicon pairs were obtained from 100
pairs of the normal and cancer DNAs using 15 methylation
primer sets, of which 617 (41%) showed a similar frequen-
cy of hypermethylation (320, 20%) or hypomethylation
(297, 21%) changes in the cancer DNA. Nine CpG-island
margins (900 CpG amplicon pairs) and six non-island CpG
sites (600 CpG amplicon pairs) were mainly hypermethylat-
ed (hyper- vs. hypo-methylation, 25% vs. 16%) and hypo-
methylated (hyper- vs. hypo-methylation, 16% vs. 26%) in
cancer tissues, respectively (p<0.0001).
A total of 225 CpG amplicon pairs from nine CpG-island
margins and a total of 150 CpG amplicon pairs from six
non-island CpG sites were analyzed in 25 cancer tissues
tested for each cancer type. Fig. 3 shows the relationships
between the transitional-CpG methylation status and the
level of LOH analyzed in the four cancer types. A compari-
son of the four cancer types showed that hypomethylation
of the CpG-island margins tend to be more common in gas-
tric (21%) and nasopharyngeal (18%) cancers than in colonic
(13%), and mammary (10%) cancers (p=0.009). The hypo-
methylation of the non-island CpG sites was more frequent
A
Fig. 3. Comparison of the transitional-CpG methylation changes between the different cancer types (A) and between cancers with high-
level (H) and low-level (L) chromosomal losses (B). The criteria for the level of chromosomal losses are described in the legend of Fig. 2.
The frequency of the methylation changes in the six non-island CpG sites and nine CpG-island margins are indicated as a percentage in
25 cancer cases. p values were calculated for the differences in the frequency of methylation changes between four cancer types by a
chi-square test.
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in the gastric (32%) and colonic (33%) cancers than in the
mammary (21%) and nasopharyngeal (19%) cancers (p=
0.013). Hypomethylation of the transitional-CpG sites fre-
quent in gastric cancers was associated with high-level chro-
mosomal losses (CpG-island margins, p<0.0001; non-island
CpG sites, p=0.006).
Methylation status of transitional CpGs in normal somatic
tissues
The methylation status of the 15 transitional-CpG sites,
including the methylation data reported previously (9, 10),
was analyzed comparatively in the 11 somatic tissue types
(Fig. 4). The mean level of transitional-CpG methylation
estimated in three or five individuals was calculated for each
tissue type. The somatic tissues were classified into the three
germ-layer lineages to determine the lineage-dependent
pattern of transitional-CpG methylation. Eight of the nine
CpG-island margins were completely unmethylated or most
hypomethylated in the mesodermal lineage and all six non-
island CpG sites were the most hypermethylated. Mean-
while, seven CpG-island margins were most hypermethy-
lated in the endodermal lineage and three non-island CpG
sites were the most hypomethylated. The CpG-island mar-
gins were slightly hypomethylated in the ectodermal lineage
compared with the endodermal lineage.
Analysis of the transcript populations based on CpG
islands and nearby retroelements
The number of active genes and the mean number of ex-
pressed tags (i.e. mean transcript number) per active gene
were used to access the net output of transcription in each
tissue (Fig. 5A). A total of 15,770 active genes obtained from
the SAGE data were categorized according to the presence
or absence of CpG islands. The number of active genes in
both gene groups with and without CpG islands was higher
in the embryonic stem cells than in the placenta. The tran-
script number per active gene in the gene group with CpG
islands was higher in the embryonic stem cells while that in
the gene group lacking CpG islands was higher in the pla-
centa. The somatic tissues also showed an inverse correlation
between the total number of active genes and the transcript
number per active gene in the gene group lacking CpG
islands. The genes with CpG islands showed a low number
of active genes as well as the transcript number per active
gene in the normal stomachs compared with the other nor-
mal tissues.
Fig. 4. Methylation profiles of 15 transitional CpG sites examined in 11 tissue types. The estimation of CpG methylation obtained using
semiquantitative methylation-specific PCR were divided into five levels (     , 0-20%;     , 21-40%;     , 41-60%;     , 61-80%;     , 81-100%).
Differences in the mean level of methylation between the most highly methylated and least methylated tissue types are indicated by closed
bars. Somatic tissues were classified into three germ-layer lineages, endoderm (EN), mesoderm (ME), and ectoderm (EC).
Genes
Methylation difference
between tissues
Endoderm
Proximal
stomach
Distal
stomach
Proximal
colon Larynx Distal
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marrow Fat Ovary Testis
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MAGEA2
TFF2
DDX53
With CpG island
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All cancers tended to show an increase in the number of
active genes accompanying the down-regulation of tissue-
specific strong gene expression. Gastric and colonic cancers
increased the number of active genes with and without CpG
islands. Gastric cancers increased the transcript number per
active gene in the gene group containing CpG islands and
decreased the transcript number in the gene group lacking
CpG islands. Colonic cancers showed a lower transcript num-
ber per active gene in both the gene groups with and with-
out CpG islands. Mammary cancers showed a slightly high-
er number of the active genes in the gene group with CpG
islands and a lower transcript number per active gene in the
gene group lacking CpG islands.
The type of retroelements in close proximity to the pro-
moter was demarcated using non-overlapping 3-kb windows
moving away from the transcription start site. The CpG-
island-positive genes were classified into three gene groups
according to the type of retroelements occupying a 3-kb win-
dow as follows; L1, Alu, and L1-Alu combination. The CpG-
island-negative genes with L1 or L1-Alu in a 3-kb window
Fig. 5. Transcript populations of the embryonic stem cells, placenta, and somatic tissues in the SAGE libraries. (A) The number of the active
genes and the number of tags expressed per active gene were calculated separately according to the presence or absence of CpG
islands. The mean values of two to eight tissues are indicated for each tissue type. N, normal; C, cancer. All information about the SAGE
data is listed in Supplementary Table 4. (B) Transcripts of the CpG-island-negative genes close to the L1 and Alu retroelements. The genes
lacking the CpG islands were grouped according to the type of retroelements round the transcription start sites. The relative proportion
of the gene-group transcripts in the total transcript population was calculated for each normal and cancer tissue. The transcript data of
the nasopharynx was obtained from the EST libraries. All information regarding individual tissues is listed in Supplementary Table 4. 
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were collectively classified as the L1-close gene group. The
number of active genes was high in order of the breast, colon,
and stomach irrespective of the type of nearby retroelements
and the presence or absence of CpG islands (Table 1). There
was an inverse correlation between the number of active genes
and the transcript number per active gene in the CpG-island-
negative gene group close to L1 elements in normal tissues.
There was a similar number of active genes and a similar
transcript number per active gene in each gene group in all
cancers.
SAGE or the expressed sequence tag (EST) data was used
to calculate the relative proportion of CpG-island-negative
gene transcripts in the total transcripts (Fig. 5B). The CpG-
island-negative gene group close to the L1 elements was
transcribed in the highest proportion (13-27%) in the stom-
ach and in the lowest proportion in the embryonic stem cells
(3-4%). In all cancers, the proportion of CpG-island-nega-
tive L1-close gene transcripts reached intermediate levels
(4-9%) compared with the placenta (9-12%) and embryon-
ic stem cells (3-4%).
Tissue-specific gene expression profiles in embryo and
somatic tissues
The Pearson’s correlation coefficients of the transcript num-
bers of the individual genes between the somatic tissues and
either embryonic stem cells or the placenta were calculated
to determine the similarities in the gene expression profiles
(Table 2). The transcript numbers of the CpG-island-nega-
tive genes in the placenta and embryonic stem cells were not
associated with those in the stomach but strongly or weakly
associated with those in the colon and breast. There was no
or weak association between the transcript numbers of the
CpG-island-positive genes close to L1 elements in the gas-
trointestinal tissues and placenta or in the breast tissues and
embryonic stem cells. In all cancer tissues, including gastroin-
testinal cancers, the transcript numbers of both the genes
with and without CpG islands were strongly associated with
those of the embryonic stem cells as well as the placenta. 
DISCUSSION
In this study, we investigated the four types of human can-
cers-gastric, colonic, mammary, and nasopharyngeal cancers
using LOH and MSP to delineate the relationship of chro-
mosomal losses with the DNA methylation and transcrip-
tion profiles in cancers. The four human cancers can be dis-
tinguished for their preferred types and extents of LOH (Fig.
1), providing potential clues on the presence of cancer-type-
dependent tumor suppressor genes. With respect to methy-
lation changes, there was a similar tendency for the 15 tran-
sitional CpG sites in the four cancers; the hypermethylation
of nine CpG-island margins and the hypomethylation of six
non-island CpG sites (Fig. 2). A series of evidence proposes
that retroelement methylation is prevented at the unmethy-
lated CpG islands and promote the methylation of the non-
island-CpG sites (1, 2, 17, 18). Both CpG-island margin
hypermethylation and non-island CpG hypomethylation
might be associated with the genome-wide pattern of retroele-
ment methylation (6, 19). In addition, chromosomal losses
reducing the active genes appear to influence the total num-
ber of active genes in the cancer genome through global methy-
lation changes in the gene-control regions.
The hypomethylation of both the CpG-island margins
and non-island-CpG sites was more common in gastric can-
cers than in other cancer types. The SAGE data demonstrat-
ed an increase in the number of active genes with and with-
out CpG islands in gastric cancers and their expression pro-
files were similar to those of embryonic stem cells and the
placenta (Table 1, 2). It is well-known that there are many
similarities exist between carcinogenesis and embryogene-
sis, such as invasive growth and multi-lineage differentiation
(20-23). The hypomethylation of the transitional-CpG sites
in the gene-control regions may allow the reactivation of
cell-intrinsic developmental programs that are repressed by
transitional-CpG methylation in the adult somatic tissues.
In gastric cancer, the cases with high-level of chromoso-
mal losses showed a significantly higher extent of hypomethy-
lation for both the CpG-island margins and non-island CpG
sites (Fig. 3). Meanwhile, the colon, breast, and nasophar-
ynx with a higher number of active genes showed no signif-
icant association between the chromosomal losses and methy-
lation changes in their cancer tissues. The different epige-
netic and transcriptional changes in different cancer types
are likely to commonly drive the universal malignant traits
through the reactivation of the dormant cell-intrinsic pro-
grams for embryonic implantation and placentation (9, 12,
13). Therefore, the hypomethylation of the transitional-CpG
sites associated with chromosomal losses might be uniquely
prevalent in gastric cancers because the stomach with a small
number of active genes needs an increase in the active genes
for cancer evolution. 
In the stomach, high-level chromosomal losses can cause
the excessive reduction of active gene copies and have an
adverse effect on cell viability. The hypomethylation of the
transitional-CpG sites related to the global methylation pat-
tern would increase the number of active genes as well as
facilitate the reactivation of the inactive genes. In case of the
normal colon with a large number of active genes, it is like-
ly that the hypomethylation of the transitional-CpG sites in
colonic cancers is not necessarily associated with high-level
chromosomal losses. Similarly, the gene-dose-dependent
methylation changes in both the genes with and without
CpG islands appear to be relatively less dominant in mam-
mary and nasopharyngeal cancers because their normal tis-
sues already have a sufficient number of active genes.
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on the three germ-layer origins, the CpG-island margins,
most of which are close to L1 elements or are bordered by
retroelements at a long distance (Supplementary Fig. 1), were
more methylated in the endoderm-derived tissues than in
the other tissues (Fig. 4). In particular, the normal stomach
had a lower number of active genes and higher transcript
number per active genes in the CpG-island-negative gene
group close to L1 elements. Previous studies suggest that
during embryogenesis and development, highly repetitive
Alu and L1 elements trigger genome-wide methylation as
well as the spreading of methylation signals into the flank-
ing CpGs (9, 24, 25). The dense methylation of the transi-
tional-CpG markers indicates long-distance L1 methylation
in the stomach, which is necessary for maintaining a small
number of active genes as well as repressing a large number
of genes (Table 3). Therefore, the tissue-specific methylation
profiles established in consistent with the tissue-specific num-
ber of active genes are likely to be disturbed with chromo-
somal losses reducing the active genes in cancers.
With the accuracy of the SAGE data, the biased number
of active genes is attributable to the total number of tran-
script tags counted in the SAGE library (26). However, both
the SAGE and microarray data showed the strong expression
of a small number of the active genes without CpG islands
in the normal stomach (data not shown). The non-island-
CpG sites were hypomethylated in the normal stomach where-
as the hypermthylation of the CpG-island margins in the
normal stomach (Fig. 4). This pattern of transitional-CpG
methylation appears to be a useful epigenetic way for the
maintenance of tissue-specific strong expression along with
the inactivation of a large number of genes. Thus, it is pos-
sible that a set of the transitional-CpG sites examined in this
study can serve as a global epigenetic marker for the total
number of active genes established under the influence of
genome-wide retroelement methylation.
Taken together, unilateral chromosomal losses, which reflect
a reduction in the gene dose, might lead to the hypomethy-
lation of the gene-control regions and an increase in the num-
ber of active genes in gastric cancers. The hypomethylation
changes in the transitional CpG sites appear to facilitate the
reactivation of cell-intrinsic embryogenesis-development
programs in cancer cells as well. The results of this study
explain how the LOH events initiate the invasive outgrowth
of cancer cells similar to embryonic implantation and pla-
centation.
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Gene symbol Gene description Accession no.
Chromosome
locus
MSP 
position (kb)
Methylation
studies
MAGEA2 Melanoma antigen family A, 2 NM_005361 Xq28 0.0 (1)
TFF2 Trefoil factor 2 (spasmolytic protein 1) NM_005423 21q22 -0.2 (2)
DDX53 DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 NM_182699 Xq22.11 0.0 (1)
MSLN Mesothelin isoform 2 precursor NM_013404 16q13 -0.8 (2)
MASPIN Serpin peptidase inhibitor, clade B (ovalbumin), member 5 NM_002639 18q21 -0.3 (1)
BGLAP Osteocalcin NM_199173 1q23.1 -0.4 (3)
MUC8 Mucin 8, tracheobronchial U14383
a 12q24 +0.2 (2)
KIAA1752 Homo sapiens mRNA for KIAA1752 protein AB051539
a 16q12 +0.4 (2)
CDKN2A Cyclin-dependent kinase inhibitor 2A  NM_000077 9p21 -1.5 (1)
ESR2 Estrogen receptor 2 (ER beta) NM_001437 14q23 -0.9 (2)
PPARG Peroxisome proliferative activated receptor NM_138711  3p25.1 -1.5 (3)
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2  NM_000249 3p22 -1.0 (1)
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) NM_004360 16q22 0.1 (1)
VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor NM_000376 12q13 -0.7 (2)
RUNX3 Runt-related transcription factor 3 NM_004350 1p36 -1.7 (2)
Supplementary  Table 1 List of 15 genes examined by methylation analysis
a, GenBank accession number.
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CpG sites Forward (5′ to 3′ ) Reverse (5′ to 3′ )
Amplicon size
(bp)
Tm (
oC)
MAGEA2 U GTTAGGTTGTTGTTTAGGGT CCAAAAAAATCACAAACCCA 92 59
M GCGTTTGTTTTTTTTCGTCGAC AAATCACGAACCCGAATATAACG 108 61
TFF2 U GGTAGTTGTGTTTTGTGTAGGT CACATAACCAATTTTCCACA 130 56
M GGTAGTTGTGTTTTGTGTAGGC CACGTAACCGATTTTCCACG 130 62
DDX53 U TGGTTTTTGGGGTAATTTTTGT CAAATCTACAACCTATTTCCCA 105 57
M TTTTATACGATTCGGAATTCGAC CAAATCTACGACCTATTTCCCG 136 58
MSLN U GGAGAGATTAGAGATGATTGTTGT CATAAACTCTTATCCCCAATACA 103 55
M GGAGAGATTAGAGATGATCGTCGC CGTAAACTCTTATCCCCAATACG 103 60
MASPIN  U GAATATTTTATTTTTTGGTTTTGTG AAAAAACCTCCAACATATTCA 111 56
M TTATTTTTCGGTTTTGCG AAAAAACCTCCAACATATTCG 104 54
BGLAP U AGGGTAGGGTTTGAGTTGTT AATACCTCACAATACCCCCA 85 58
M AGGGTAGGGTTTGAGTCGTC AATACCTCGCAATACCCCCG 85 58
MUC8 U GGTAGGAGTTATTAGGAGAGTATT AATACAAACACTCACCACCTAACC 140 55
M GGTAGGAGTTATTAGGAGAGTATC AATACAAACGCTCACCGCCTAACC 140 60
KIAA1752 U TAATGGTTTTTGAGGATTGAGATTG CACAAACTATTATCAACCAATCAC 103 58
M TAATGGTTTTTGAGGATTGAGATC CACAAACTATTATCAACCGATCAC 103 62
CDKN2A U TTGGGATTAGGTTTAGTTTTGG CTATAAAACCCTATCAACTCACAC 130 58
M TCGGGATTAGGTTTAGTTTCG AAACCCTATCGACTCACGCT 125 60
ESR2 U TTTTTTTTAAGGATTTTGTGTGT ACTAAAAATACACATTCCACCA 111 56
M TTTTTTTAAGGATTTCGCGCGC CCAACTAAAAATACACGTTCCACC 113 58
PPARG U GGTTAGGTTTTGTGTTTTGATGT CCTAACTACACACTCCATCCA 103 58
M GGTTAGGTTTTGTGTTTTGACGC CCTAACTACGCGCTCCATCCG 103 56
MLH1 U GATTTTAGGATTGTTGATATGAGT AAACTACCTCCTAATCTTTATCCA 126 58
M GATTTTAGGATTGTCGATATGAGC AACTACCTCCTAATCTTTATCCG 125 58
CDH U GGTGAATTTTTAGTTAATTAGTGGTAT TCACAAATACTTTACAATTCCAAC 108 56
M TGAATTTTTAGTTAATTAGCGGTAC ACAAATACTTTACAATTCCGACG 104 58
VDR U TGGTAGTGATTGTGGTTGATTAT CCTCACACCAATACCACAAAACA 130 58
M GGTAGCGATCGCGGTTGATTAC CTCACGCCGATACCACGAAACG 128 58
RUNX3 U TGGGGTTAGATTTTTGTTGTTTTT ATAAAATCTTACAACCACCATCA 107 56
M CGGGGTTAGATTTTCGTTGTTTTC ATAAAATCTTACGACCACCGTCG 107 58
Supplementary  Table 2 Sequences and PCR condition of the unmethylation (U) and methylation (M)-specific primer setsGenetic and Epigenetic Changes Related with Transcript Number in Gastric Cancer 1081
Tissue
Sample
ID
Sex Age
Genoty-
pe
a
Analysis of loss of heterozygosity
�
No. of 
LOH
Chromo-
some 3
Chromo-
some 4
Chromo-
some 5
Chromo-
some 8
Chromo-
some 9
Chromo-
some 13
Chromo-
some 17
Chromo-
some 18
Stomach S1 Male 57 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
S2 Male 65 LOH-H 7 LOH+ LOH+ LOH+ LOH- LOH+ LOH+ LOH+ LOH+
S3 Female 35 LOH-H 7 LOH+ LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH+
S4 Male 65 LOH-H 7 LOH+ LOH+ LOH+ LOH- LOH+ LOH+ LOH+ LOH+
S5 Male 60 LOH-H 6 LOH- LOH+ LOH+ LOH- LOH+ LOH+ LOH+ LOH+
S6 Female 64 LOH-H 6 LOH+ LOH+ LOH- LOH- LOH+ LOH+ LOH+ LOH+
S7 Male 74 LOH-H 6 LOH- LOH+ LOH+ LOH+ LOH- LOH+ LOH+ LOH+
S8 Female 57 LOH-H 5 LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH- LOH-
S9 Male 63 LOH-H 5 LOH- LOH- LOH+ LOH+ LOH+ LOH- LOH+ LOH+
S10 Male 67 LOH-H 5 LOH- LOH- LOH+ LOH+ LOH+ LOH- LOH+ LOH+
S11 Male 75 LOH-H 4 LOH+ LOH+ LOH- LOH- LOH- LOH- LOH+ LOH+
S12 Female 74 LOH-H 4 LOH- LOH+ LOH+ LOH- LOH- LOH- LOH+ LOH+
S13 Male 76 LOH-H 4 LOH- LOH- LOH- LOH+ LOH+ LOH- LOH+ LOH+
S14 Male 61 LOH-H 4 LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH-
S15 Male 64 LOH-L 3 LOH+ LOH- LOH- LOH- LOH- LOH+ LOH- LOH+
S16 Male 49 LOH-L 3 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH+ LOH-
S17 Male 57 LOH-L 3 LOH- LOH- LOH+ LOH- LOH- LOH- LOH+ LOH+
S18 Male 48 LOH-L 3 LOH- LOH+ LOH- LOH- LOH- LOH- LOH+ LOH+
S19 Male 64 LOH-L 2 LOH- LOH- LOH- LOH+ LOH+ LOH- LOH- LOH-
S20 Female 66 LOH-L 2 LOH- LOH- LOH- LOH- LOH- LOH+ LOH+ LOH-
S21 Male 62 LOH-L 2 LOH- LOH- LOH- LOH- LOH- LOH+ LOH+ LOH-
S22 Male 64 LOH-L 2 LOH- LOH- LOH+ LOH- LOH+ LOH- LOH- LOH-
S23 Female 42 LOH-L 1 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH+
S24 Male 59 LOH-L 1 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH+
S25 Male 68 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
Colon C1 Male 71 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
C2 Male 71 LOH-H 7 LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
C3 Male 44 LOH-H 6 LOH+ LOH+ LOH- LOH+ LOH- LOH+ LOH+ LOH+
C4 Female 53 LOH-H 6 LOH+ LOH+ LOH+ LOH+ LOH- LOH- LOH+ LOH+
C5 Male 61 LOH-H 5 LOH+ LOH+ LOH- LOH+ LOH+ LOH- LOH+ LOH-
C6 Female 60 LOH-H 5 LOH+ LOH+ LOH- LOH+ LOH- LOH+ LOH+ LOH-
C7 Female 40 LOH-H 5 LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH+
C8 Male 58 LOH-H 5 LOH- LOH- LOH- LOH+ LOH+ LOH+ LOH+ LOH+
C9 Male 67 LOH-H 4 LOH- LOH- LOH+ LOH+ LOH- LOH- LOH+ LOH+
C10 Female 59 LOH-H 4 LOH+ LOH- LOH- LOH- LOH- LOH+ LOH+ LOH+
C11 Male 67 LOH-H 4 LOH- LOH- LOH+ LOH+ LOH- LOH- LOH+ LOH+
C12 Female 73 LOH-H 4 LOH- LOH+ LOH- LOH- LOH+ LOH- LOH+ LOH+
C13 Female 56 LOH-L 3 LOH- LOH- LOH+ LOH+ LOH+ LOH- LOH- LOH-
C14 Male 63 LOH-L 3 LOH- LOH- LOH+ LOH- LOH+ LOH- LOH+ LOH-
C15 Male 64 LOH-L 3 LOH- LOH- LOH- LOH- LOH- LOH+ LOH+ LOH+
C16 Female 70 LOH-L 2 LOH+ LOH- LOH- LOH- LOH+ LOH- LOH- LOH-
C17 Female 75 LOH-L 2 LOH- LOH- LOH- LOH- LOH- LOH- LOH+ LOH+
C18 Female 78 LOH-L 2 LOH- LOH+ LOH- LOH+ LOH- LOH- LOH- LOH-
C19 Female 29 LOH-L 2 LOH- LOH- LOH+ LOH- LOH- LOH+ LOH- LOH-
C20 Male 30 LOH-L 2 LOH- LOH- LOH- LOH- LOH- LOH- LOH+ LOH+
C21 Female 64 LOH-L 1 LOH- LOH- LOH- LOH- LOH- LOH+ LOH- LOH-
C22 Male 75 LOH-L 1 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH+
C23 Female 46 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
C24 Female 46 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
C25 Female 75 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
Breast B1 Female 41 LOH-H 7 LOH- LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
B2 Female 64 LOH-H 7 LOH- LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
B3 Female 47 LOH-H 6 LOH- LOH+ LOH+ LOH+ LOH- LOH+ LOH+ LOH+
B4 Female 67 LOH-H 5 LOH- LOH+ LOH+ LOH+ LOH+ LOH+ LOH- LOH-
B5 Female 50 LOH-H 5 LOH+ LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH-
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B6 Female 67 LOH-H 4 LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH- LOH-
B7 Female 59 LOH-H 4 LOH- LOH- LOH+ LOH+ LOH- LOH+ LOH+ LOH-
B8 Female 31 LOH-H 4 LOH+ LOH+ LOH- LOH- LOH- LOH+ LOH+ LOH-
B9 Female 37 LOH-H 4 LOH- LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH+
B10 Female 56 LOH-L 3 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH+ LOH-
B11 Female 55 LOH-L 3 LOH- LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH-
B12 Female 51 LOH-L 3 LOH- LOH+ LOH- LOH+ LOH- LOH- LOH+ LOH-
B13 Female 33 LOH-L 3 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH+ LOH-
B14 Female 60 LOH-L 3 LOH+ LOH+ LOH- LOH- LOH- LOH+ LOH- LOH-
B15 Female 56 LOH-L 2 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH- LOH-
B16 Female 52 LOH-L 2 LOH- LOH- LOH- LOH+ LOH- LOH+ LOH- LOH-
B17 Female 50 LOH-L 2 LOH+ LOH- LOH- LOH- LOH- LOH+ LOH- LOH-
B18 Female 42 LOH-L 2 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH- LOH-
B19 Female 55 LOH-L 1 LOH- LOH- LOH- LOH+ LOH- LOH- LOH- LOH-
B20 Female 39 LOH-L 1 LOH- LOH- LOH+ LOH- LOH- LOH- LOH- LOH-
B21 Female 44 LOH-L 1 LOH+ LOH- LOH- LOH- LOH- LOH- LOH- LOH-
B22 Female 50 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
B23 Female 43 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
B24 Female 63 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
B25 Female 49 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
Nasopharynx N1 Male 56 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
N2 Male 48 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
N3 Male 55 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
N4 Male 71 LOH-H 8 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
N5 Male 72 LOH-H 7 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH-
N6 Male 50 LOH-H 7 LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH+ LOH+
N7 Female 71 LOH-H 6 LOH- LOH+ LOH+ LOH+ LOH- LOH+ LOH+ LOH+
N8 Male 56 LOH-H 6 LOH+ LOH+ LOH+ LOH+ LOH- LOH- LOH+ LOH+
N9 Male 62 LOH-H 6 LOH+ LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH-
N10 Male 65 LOH-H 6 LOH+ LOH+ LOH+ LOH+ LOH+ LOH+ LOH- LOH-
N11 Male 48 LOH-H 6 LOH+ LOH- LOH+ LOH+ LOH+ LOH+ LOH- LOH+
N12 Male 65 LOH-H 6 LOH+ LOH+ LOH+ LOH+ LOH+ LOH- LOH+ LOH-
N13 Male 66 LOH-H 6 LOH+ LOH+ LOH+ LOH+ LOH+ LOH- LOH- LOH+
N14 Male 58 LOH-H 5 LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH+
N15 Male 64 LOH-H 5 LOH+ LOH- LOH+ LOH- LOH+ LOH+ LOH- LOH+
N16 Male 47 LOH-H 5 LOH+ LOH- LOH- LOH+ LOH+ LOH+ LOH+ LOH-
N17 Male 67 LOH-H 5 LOH- LOH- LOH+ LOH- LOH+ LOH+ LOH+ LOH+
N18 Male 51 LOH-H 4 LOH+ LOH- LOH- LOH- LOH- LOH+ LOH+ LOH+
N19 Female 62 LOH-L 3 LOH- LOH- LOH- LOH+ LOH+ LOH- LOH+ LOH-
N20 Female 45 LOH-L 3 LOH- LOH- LOH- LOH+ LOH+ LOH+ LOH- LOH-
N21 Male 46 LOH-L 2 LOH- LOH- LOH+ LOH- LOH- LOH- LOH- LOH+
N22 Male 47 LOH-L 2 LOH+ LOH- LOH- LOH+ LOH- LOH- LOH- LOH-
N23 Female 59 LOH-L 1 LOH- LOH- LOH- LOH- LOH+ LOH- LOH- LOH-
N24 Male 44 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
N25 Female 74 LOH-L 0 LOH- LOH- LOH- LOH- LOH- LOH- LOH- LOH-
Stomach S1 Normal Level 5 Level 2 Level 5 Level 4 Level 3 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 2
Cancer Level 5 Level 2 Level 4 Level 5 Level 4 Level 3 Level 5 Level 2 Level 1 Level 1 Level 1 Level 1 Level 1 Level 2 Level 3
S2 Normal Level 5 Level 3 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 2
Cancer Level 2 Level 2 Level 3 Level 3 Level 2 Level 3 Level 3 Level 3 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 4
S3 Normal Level 5 Level 2 Level 4 Level 4 Level 4 Level 4 Level 5 Level 2 Level 2 Level 1 Level 1 Level 2 Level 2 Level 2 Level 2
Cancer Level 4 Level 3 Level 4 Level 2 Level 2 Level 4 Level 3 Level 3 Level 1 Level 1 Level 1 Level 2 Level 1 Level 1 Level 4
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S4 Normal Level 5 Level 2 Level 5 Level 3 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 2 Level 2
Cancer Level 4 Level 2 Level 4 Level 3 Level 3 Level 2 Level 4 Level 3 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 4
S5 Normal Level 5 Level 2 Level 4 Level 5 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1
Cancer Level 2 Level 2 Level 2 Level 3 Level 2 Level 2 Level 4 Level 1 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
S6 Normal Level 5 Level 3 Level 4 Level 4 Level 2 Level 3 Level 5 Level 1 Level 2 Level 1 Level 2 Level 2 Level 2 Level 1 Level 2
Cancer Level 3 Level 3 Level 3 Level 3 Level 2 Level 4 Level 4 Level 1 Level 2 Level 1 Level 2 Level 2 Level 2 Level 1 Level 3
S7 Normal Level 5 Level 2 Level 4 Level 4 Level 4 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 4 Level 1 Level 2 Level 1
Cancer Level 5 Level 2 Level 4 Level 4 Level 2 Level 2 Level 4 Level 2 Level 2 Level 1 Level 1 Level 4 Level 1 Level 2 Level 2
S8 Normal Level 5 Level 5 Level 4 Level 4 Level 4 Level 4 Level 5 Level 2 Level 2 Level 1 Level 2 Level 3 Level 2 Level 2 Level 2
Cancer Level 2 Level 4 Level 4 Level 5 Level 2 Level 3 Level 5 Level 2 Level 1 Level 1 Level 2 Level 3 Level 1 Level 1 Level 2
S9 Normal Level 4 Level 2 Level 4 Level 4 Level 2 Level 3 Level 5 Level 2 Level 2 Level 3 Level 2 Level 2 Level 1 Level 2 Level 2
Cancer Level 1 Level 2 Level 5 Level 4 Level 2 Level 3 Level 2 Level 2 Level 1 Level 2 Level 1 Level 2 Level 2 Level 1 Level 4
S10 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 1 Level 1 Level 4 Level 2 Level 1 Level 2
Cancer Level 5 Level 1 Level 5 Level 3 Level 1 Level 3 Level 4 Level 2 Level 2 Level 1 Level 1 Level 3 Level 2 Level 1 Level 5
S11 Normal Level 5 Level 3 Level 5 Level 4 Level 2 Level 3 Level 5 Level 3 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 2
Cancer Level 3 Level 2 Level 3 Level 3 Level 2 Level 4 Level 4 Level 3 Level 3 Level 1 Level 1 Level 2 Level 2 Level 2 Level 3
S12 Normal Level 5 Level 3 Level 4 Level 4 Level 2 Level 3 Level 5 Level 2 Level 2 Level 2 Level 2 Level 2 Level 3 Level 2 Level 2
Cancer Level 5 Level 2 Level 4 Level 3 Level 2 Level 3 Level 5 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 1 Level 3
S13 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 4 Level 4 Level 2 Level 3 Level 2 Level 2 Level 4 Level 1 Level 1 Level 2
Cancer Level 5 Level 3 Level 4 Level 4 Level 3 Level 4 Level 3 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 1 Level 2
S14 Normal Level 5 Level 2 Level 4 Level 5 Level 2 Level 3 Level 5 Level 2 Level 1 Level 1 Level 2 Level 3 Level 2 Level 1 Level 4
Cancer Level 5 Level 3 Level 4 Level 4 Level 3 Level 3 Level 5 Level 1 Level 2 Level 2 Level 3 Level 3 Level 2 Level 1 Level 4
S15 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 4 Level 2 Level 3 Level 1 Level 1 Level 1 Level 1 Level 2 Level 2
Cancer Level 5 Level 1 Level 5 Level 5 Level 3 Level 3 Level 4 Level 3 Level 5 Level 1 Level 1 Level 1 Level 2 Level 1 Level 4
S16 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 5 Level 2 Level 2 Level 1 Level 2 Level 2 Level 2 Level 1 Level 2
Cancer Level 5 Level 2 Level 2 Level 5 Level 2 Level 3 Level 4 Level 3 Level 2 Level 1 Level 2 Level 1 Level 2 Level 1 Level 3
S17 Normal Level 5 Level 2 Level 5 Level 3 Level 2 Level 4 Level 4 Level 2 Level 2 Level 1 Level 1 Level 2 Level 1 Level 2 Level 2
Cancer Level 5 Level 2 Level 4 Level 3 Level 2 Level 4 Level 4 Level 2 Level 3 Level 2 Level 2 Level 2 Level 1 Level 3 Level 4
S18 Normal Level 5 Level 2 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 2 Level 2
Cancer Level 5 Level 2 Level 4 Level 4 Level 2 Level 4 Level 5 Level 2 Level 1 Level 2 Level 3 Level 3 Level 1 Level 2 Level 2
S19 Normal Level 4 Level 2 Level 4 Level 2 Level 1 Level 3 Level 4 Level 2 Level 1 Level 2 Level 2 Level 2 Level 2 Level 1 Level 4
Cancer Level 2 Level 2 Level 5 Level 2 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 4 Level 2 Level 2 Level 5
S20 Normal Level 5 Level 2 Level 4 Level 4 Level 2 Level 3 Level 5 Level 1 Level 2 Level 2 Level 1 Level 2 Level 1 Level 2 Level 4
Cancer Level 4 Level 3 Level 2 Level 4 Level 2 Level 4 Level 5 Level 1 Level 2 Level 2 Level 1 Level 2 Level 2 Level 2 Level 4
S21 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 4 Level 3 Level 2 Level 1 Level 1 Level 2 Level 1 Level 2 Level 2
Cancer Level 5 Level 3 Level 2 Level 5 Level 2 Level 3 Level 5 Level 4 Level 5 Level 2 Level 1 Level 4 Level 1 Level 3 Level 4
S22 Normal Level 5 Level 2 Level 5 Level 2 Level 2 Level 3 Level 4 Level 2 Level 2 Level 1 Level 1 Level 3 Level 2 Level 2 Level 4
Cancer Level 5 Level 2 Level 5 Level 2 Level 2 Level 2 Level 4 Level 2 Level 2 Level 1 Level 1 Level 4 Level 2 Level 1 Level 5
S23 Normal Level 5 Level 3 Level 5 Level 3 Level 3 Level 3 Level 4 Level 2 Level 2 Level 2 Level 1 Level 4 Level 1 Level 1 Level 2
Cancer Level 5 Level 2 Level 5 Level 3 Level 3 Level 2 Level 4 Level 2 Level 2 Level 2 Level 2 Level 4 Level 1 Level 1 Level 2
S24 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 5 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 3 Level 2
Cancer Level 5 Level 3 Level 4 Level 5 Level 2 Level 4 Level 4 Level 2 Level 4 Level 2 Level 3 Level 4 Level 1 Level 1 Level 4
S25 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 4 Level 4 Level 1 Level 2 Level 3 Level 1 Level 4 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 5 Level 1 Level 4 Level 5 Level 1 Level 2 Level 2 Level 1 Level 5 Level 1 Level 2 Level 4
Colon C1 Normal Level 5 Level 1 Level 4 Level 5 Level 2 Level 4 Level 5 Level 3 Level 1 Level 2 Level 1 Level 4 Level 1 Level 3 Level 2
Cancer Level 2 Level 3 Level 4 Level 5 Level 1 Level 4 Level 3 Level 2 Level 1 Level 2 Level 1 Level 2 Level 1 Level 2 Level 4
C2 Normal Level 5 Level 2 Level 5 Level 4 Level 1 Level 4 Level 5 Level 2 Level 2 Level 3 Level 1 Level 3 Level 1 Level 2 Level 2
Cancer Level 4 Level 2 Level 5 Level 2 Level 1 Level 4 Level 5 Level 3 Level 2 Level 2 Level 1 Level 4 Level 1 Level 2 Level 3
C3 Normal Level 5 Level 2 Level 5 Level 5 Level 2 Level 4 Level 4 Level 2 Level 1 Level 2 Level 2 Level 4 Level 1 Level 3 Level 2
Cancer Level 3 Level 2 Level 5 Level 3 Level 2 Level 3 Level 4 Level 2 Level 1 Level 2 Level 2 Level 4 Level 1 Level 1 Level 2
C4 Normal Level 4 Level 2 Level 4 Level 4 Level 2 Level 4 Level 4 Level 1 Level 2 Level 2 Level 2 Level 2 Level 1 Level 2 Level 1
Cancer Level 4 Level 2 Level 3 Level 4 Level 1 Level 4 Level 4 Level 1 Level 1 Level 3 Level 2 Level 1 Level 1 Level 4 Level 2
C5 Normal Level 5 Level 3 Level 4 Level 5 Level 1 Level 4 Level 4 Level 2 Level 2 Level 2 Level 1 Level 3 Level 2 Level 2 Level 1
Cancer Level 2 Level 2 Level 3 Level 5 Level 2 Level 4 Level 5 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 1
C6 Normal Level 5 Level 3 Level 4 Level 5 Level 2 Level 3 Level 4 Level 2 Level 1 Level 2 Level 2 Level 3 Level 1 Level 2 Level 1
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Cancer Level 3 Level 2 Level 4 Level 5 Level 2 Level 3 Level 3 Level 2 Level 1 Level 2 Level 2 Level 3 Level 1 Level 2 Level 2
C7 Normal Level 4 Level 3 Level 4 Level 5 Level 2 Level 3 Level 4 Level 2 Level 1 Level 1 Level 3 Level 3 Level 1 Level 1 Level 2
Cancer Level 4 Level 2 Level 4 Level 5 Level 1 Level 4 Level 4 Level 2 Level 1 Level 1 Level 1 Level 3 Level 1 Level 1 Level 2
C8 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 4 Level 4 Level 2 Level 1 Level 1 Level 1 Level 2 Level 1 Level 1 Level 2
Cancer Level 5 Level 2 Level 5 Level 5 Level 2 Level 5 Level 5 Level 3 Level 1 Level 1 Level 1 Level 4 Level 1 Level 2 Level 1
C9 Normal Level 5 Level 2 Level 4 Level 5 Level 3 Level 4 Level 4 Level 2 Level 2 Level 1 Level 1 Level 3 Level 1 Level 1 Level 2
Cancer Level 2 Level 1 Level 2 Level 4 Level 3 Level 4 Level 4 Level 3 Level 3 Level 1 Level 2 Level 4 Level 1 Level 2 Level 4
C10 Normal Level 5 Level 2 Level 4 Level 5 Level 2 Level 4 Level 4 Level 2 Level 1 Level 1 Level 2 Level 4 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 4 Level 3 Level 2 Level 4 Level 3 Level 2 Level 2 Level 1 Level 2 Level 4 Level 1 Level 2 Level 3
C11 Normal Level 5 Level 1 Level 5 Level 4 Level 2 Level 4 Level 5 Level 2 Level 2 Level 1 Level 2 Level 4 Level 1 Level 2 Level 2
Cancer Level 5 Level 1 Level 5 Level 2 Level 1 Level 3 Level 4 Level 1 Level 1 Level 1 Level 2 Level 4 Level 1 Level 2 Level 2
C12 Normal Level 5 Level 3 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 1 Level 1 Level 4 Level 1 Level 1 Level 2
Cancer Level 5 Level 3 Level 4 Level 5 Level 1 Level 4 Level 5 Level 2 Level 4 Level 1 Level 1 Level 4 Level 1 Level 2 Level 3
C13 Normal Level 5 Level 4 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 2 Level 2
Cancer Level 4 Level 3 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 2 Level 3
C14 Normal Level 5 Level 2 Level 3 Level 4 Level 2 Level 4 Level 5 Level 2 Level 1 Level 2 Level 1 Level 3 Level 1 Level 2 Level 2
Cancer Level 5 Level 1 Level 2 Level 5 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 3 Level 1 Level 1 Level 4
C15 Normal Level 5 Level 2 Level 5 Level 4 Level 1 Level 4 Level 4 Level 2 Level 2 Level 2 Level 1 Level 4 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 3 Level 1 Level 4 Level 4 Level 2 Level 2 Level 2 Level 1 Level 4 Level 1 Level 2 Level 3
C16 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 4 Level 2 Level 1 Level 1 Level 1 Level 3 Level 1 Level 1 Level 2
Cancer Level 3 Level 2 Level 2 Level 4 Level 2 Level 3 Level 5 Level 2 Level 5 Level 1 Level 2 Level 3 Level 1 Level 4 Level 2
C17 Normal Level 5 Level 3 Level 4 Level 4 Level 1 Level 4 Level 4 Level 1 Level 2 Level 1 Level 2 Level 4 Level 1 Level 1 Level 2
Cancer Level 4 Level 3 Level 3 Level 3 Level 2 Level 4 Level 4 Level 1 Level 2 Level 2 Level 2 Level 2 Level 2 Level 2 Level 2
C18 Normal Level 4 Level 3 Level 5 Level 4 Level 1 Level 4 Level 4 Level 2 Level 1 Level 1 Level 1 Level 4 Level 1 Level 2 Level 2
Cancer Level 4 Level 2 Level 4 Level 5 Level 2 Level 3 Level 5 Level 2 Level 1 Level 1 Level 1 Level 2 Level 1 Level 2 Level 2
C19 Normal Level 5 Level 4 Level 5 Level 4 Level 2 Level 4 Level 4 Level 2 Level 1 Level 1 Level 2 Level 3 Level 1 Level 2 Level 1
Cancer Level 5 Level 4 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 3 Level 1 Level 3 Level 2
C20 Normal Level 5 Level 3 Level 5 Level 5 Level 2 Level 4 Level 4 Level 1 Level 1 Level 1 Level 1 Level 2 Level 2 Level 1 Level 2
Cancer Level 5 Level 3 Level 5 Level 3 Level 1 Level 4 Level 4 Level 2 Level 2 Level 1 Level 1 Level 2 Level 2 Level 1 Level 2
C21 Normal Level 5 Level 2 Level 4 Level 4 Level 2 Level 4 Level 4 Level 2 Level 1 Level 1 Level 2 Level 5 Level 2 Level 1 Level 2
Cancer Level 5 Level 1 Level 4 Level 2 Level 2 Level 3 Level 4 Level 2 Level 2 Level 3 Level 1 Level 4 Level 2 Level 5 Level 2
C22 Normal Level 4 Level 4 Level 4 Level 5 Level 2 Level 4 Level 4 Level 2 Level 2 Level 1 Level 2 Level 4 Level 1 Level 1 Level 2
Cancer Level 4 Level 3 Level 4 Level 5 Level 2 Level 5 Level 3 Level 2 Level 2 Level 1 Level 3 Level 4 Level 1 Level 2 Level 3
C23 Normal Level 5 Level 3 Level 5 Level 5 Level 1 Level 3 Level 4 Level 2 Level 1 Level 2 Level 3 Level 4 Level 1 Level 2 Level 2
Cancer Level 4 Level 2 Level 5 Level 5 Level 2 Level 3 Level 4 Level 2 Level 2 Level 2 Level 2 Level 4 Level 1 Level 2 Level 3
C24 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 4 Level 4 Level 2 Level 1 Level 3 Level 1 Level 4 Level 1 Level 1 Level 2
Cancer Level 5 Level 3 Level 4 Level 4 Level 2 Level 4 Level 5 Level 2 Level 2 Level 1 Level 1 Level 5 Level 1 Level 1 Level 3
C25 Normal Level 5 Level 3 Level 4 Level 4 Level 1 Level 4 Level 4 Level 2 Level 2 Level 1 Level 2 Level 4 Level 2 Level 2 Level 2
Cancer Level 5 Level 4 Level 4 Level 4 Level 1 Level 4 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 2 Level 2 Level 2
Breast B1 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 3 Level 4 Level 2 Level 3 Level 1 Level 2 Level 1 Level 1 Level 1 Level 4
Cancer Level 5 Level 2 Level 4 Level 3 Level 1 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 4 Level 1 Level 1 Level 4
B2 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 2 Level 5 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 1 Level 5
Cancer Level 5 Level 2 Level 5 Level 3 Level 1 Level 2 Level 4 Level 2 Level 1 Level 2 Level 2 Level 2 Level 1 Level 1 Level 5
B3 Normal Level 5 Level 3 Level 4 Level 3 Level 1 Level 3 Level 4 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 4
Cancer Level 5 Level 5 Level 4 Level 3 Level 1 Level 3 Level 4 Level 2 Level 1 Level 2 Level 2 Level 3 Level 1 Level 1 Level 4
B4 Normal Level 5 Level 3 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 3 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 4 Level 3 Level 3 Level 3 Level 2 Level 4 Level 4 Level 2 Level 3 Level 2 Level 1 Level 2 Level 2 Level 2 Level 3
B5 Normal Level 5 Level 3 Level 5 Level 3 Level 2 Level 3 Level 5 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 4 Level 3 Level 5 Level 3 Level 2 Level 3 Level 5 Level 1 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 3
B6 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 4 Level 5 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 3 Level 3 Level 3 Level 5 Level 2 Level 4 Level 4 Level 2 Level 3 Level 1 Level 3 Level 3 Level 1 Level 2 Level 3
B7 Normal Level 5 Level 2 Level 3 Level 4 Level 2 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3
Cancer Level 4 Level 2 Level 3 Level 5 Level 2 Level 4 Level 5 Level 3 Level 3 Level 1 Level 2 Level 3 Level 1 Level 3 Level 4
B8 Normal Level 5 Level 4 Level 4 Level 3 Level 2 Level 4 Level 5 Level 2 Level 3 Level 1 Level 3 Level 2 Level 1 Level 2 Level 3
Cancer Level 5 Level 4 Level 4 Level 3 Level 2 Level 4 Level 5 Level 2 Level 1 Level 1 Level 4 Level 2 Level 1 Level 2 Level 4
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B9 Normal Level 5 Level 2 Level 4 Level 4 Level 1 Level 2 Level 5 Level 2 Level 3 Level 2 Level 2 Level 1 Level 1 Level 1 Level 4
Cancer Level 5 Level 2 Level 4 Level 4 Level 1 Level 2 Level 5 Level 2 Level 3 Level 1 Level 3 Level 1 Level 1 Level 1 Level 5
B10 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 2 Level 3
Cancer Level 3 Level 3 Level 3 Level 5 Level 2 Level 4 Level 4 Level 2 Level 3 Level 1 Level 3 Level 3 Level 1 Level 2 Level 4
B11 Normal Level 5 Level 2 Level 4 Level 3 Level 1 Level 3 Level 4 Level 2 Level 3 Level 2 Level 2 Level 2 Level 1 Level 2 Level 3
Cancer Level 4 Level 3 Level 3 Level 3 Level 1 Level 4 Level 4 Level 2 Level 2 Level 1 Level 3 Level 3 Level 1 Level 2 Level 3
B12 Normal Level 5 Level 3 Level 3 Level 4 Level 1 Level 4 Level 4 Level 2 Level 3 Level 1 Level 1 Level 2 Level 1 Level 2 Level 3
Cancer Level 5 Level 2 Level 4 Level 5 Level 1 Level 4 Level 5 Level 2 Level 2 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3
B13 Normal Level 5 Level 3 Level 4 Level 3 Level 2 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 4 Level 5 Level 2 Level 3 Level 4 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3
B14 Normal Level 5 Level 3 Level 4 Level 4 Level 1 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 4 Level 3 Level 1 Level 4 Level 3 Level 2 Level 1 Level 2 Level 2 Level 4 Level 1 Level 2 Level 3
B15 Normal Level 5 Level 3 Level 4 Level 3 Level 1 Level 3 Level 5 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 1 Level 3
Cancer Level 4 Level 2 Level 4 Level 5 Level 1 Level 3 Level 4 Level 3 Level 3 Level 2 Level 2 Level 3 Level 1 Level 1 Level 4
B16 Normal Level 4 Level 3 Level 4 Level 3 Level 1 Level 4 Level 3 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 1 Level 3
Cancer Level 3 Level 3 Level 4 Level 4 Level 2 Level 4 Level 3 Level 3 Level 2 Level 1 Level 3 Level 2 Level 1 Level 1 Level 4
B17 Normal Level 5 Level 3 Level 4 Level 5 Level 1 Level 3 Level 3 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 5 Level 4 Level 4 Level 4 Level 1 Level 3 Level 3 Level 2 Level 3 Level 1 Level 2 Level 5 Level 1 Level 1 Level 3
B18 Normal Level 5 Level 2 Level 4 Level 3 Level 2 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 4 Level 3 Level 2 Level 4 Level 3 Level 2 Level 3 Level 2 Level 2 Level 4 Level 1 Level 1 Level 3
B19 Normal Level 3 Level 3 Level 4 Level 4 Level 2 Level 3 Level 4 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 3 Level 4 Level 3 Level 3 Level 1 Level 3 Level 4 Level 2 Level 3 Level 1 Level 1 Level 3 Level 1 Level 2 Level 3
B20 Normal Level 5 Level 3 Level 4 Level 3 Level 1 Level 2 Level 5 Level 2 Level 4 Level 1 Level 2 Level 1 Level 1 Level 1 Level 4
Cancer Level 5 Level 4 Level 4 Level 4 Level 1 Level 2 Level 5 Level 2 Level 4 Level 2 Level 2 Level 2 Level 1 Level 1 Level 4
B21 Normal Level 5 Level 2 Level 5 Level 4 Level 1 Level 3 Level 5 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 5 Level 4 Level 1 Level 3 Level 5 Level 2 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
B22 Normal Level 4 Level 4 Level 4 Level 3 Level 1 Level 3 Level 4 Level 1 Level 3 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 3 Level 3 Level 3 Level 5 Level 1 Level 4 Level 5 Level 2 Level 2 Level 1 Level 3 Level 2 Level 1 Level 1 Level 4
B23 Normal Level 4 Level 4 Level 4 Level 4 Level 2 Level 4 Level 3 Level 2 Level 3 Level 1 Level 1 Level 2 Level 1 Level 1 Level 4
Cancer Level 4 Level 5 Level 3 Level 4 Level 2 Level 4 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 4
B24 Normal Level 4 Level 3 Level 4 Level 3 Level 2 Level 1 Level 5 Level 2 Level 4 Level 1 Level 2 Level 1 Level 1 Level 1 Level 4
Cancer Level 4 Level 4 Level 4 Level 4 Level 2 Level 2 Level 5 Level 2 Level 4 Level 2 Level 2 Level 1 Level 1 Level 2 Level 5
B25 Normal Level 4 Level 4 Level 4 Level 4 Level 1 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 3 Level 1 Level 1 Level 3
Cancer Level 4 Level 4 Level 4 Level 5 Level 1 Level 4 Level 4 Level 2 Level 2 Level 1 Level 2 Level 1 Level 2 Level 2 Level 3
Naso- N1 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 4 Level 4 Level 2 Level 2 Level 2 Level 2 Level 3 Level 1 Level 1 Level 3
pharynx Cancer Level 4 Level 2 Level 4 Level 4 Level 1 Level 3 Level 5 Level 1 Level 1 Level 2 Level 2 Level 1 Level 1 Level 1 Level 5
N2 Normal Level 5 Level 2 Level 5 Level 3 Level 1 Level 1 Level 5 Level 2 Level 3 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 5 Level 1 Level 3 Level 5 Level 2 Level 2 Level 1 Level 1 Level 1 Level 1 Level 2 Level 5
N3 Normal Level 5 Level 2 Level 4 Level 3 Level 1 Level 2 Level 5 Level 2 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 4 Level 2 Level 1 Level 2 Level 3 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
N4 Normal Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 4 Level 2 Level 3 Level 1 Level 1 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
N5 Normal Level 5 Level 2 Level 5 Level 4 Level 1 Level 1 Level 4 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 4 Level 2 Level 5 Level 4 Level 1 Level 2 Level 4 Level 2 Level 3 Level 1 Level 1 Level 3 Level 1 Level 2 Level 2
N6 Normal Level 5 Level 4 Level 5 Level 3 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 5 Level 4 Level 1 Level 1 Level 5 Level 2 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 5
N7 Normal Level 5 Level 3 Level 5 Level 3 Level 1 Level 3 Level 4 Level 2 Level 2 Level 1 Level 2 Level 1 Level 2 Level 2 Level 2
Cancer Level 5 Level 4 Level 3 Level 4 Level 1 Level 3 Level 5 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 2 Level 2
N8 Normal Level 5 Level 4 Level 5 Level 3 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 3 Level 3 Level 1 Level 1 Level 4 Level 2 Level 1 Level 1 Level 2 Level 2 Level 1 Level 1 Level 5
N9 Normal Level 4 Level 4 Level 5 Level 3 Level 1 Level 3 Level 4 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 1 Level 2
Cancer Level 4 Level 3 Level 4 Level 3 Level 1 Level 3 Level 4 Level 1 Level 1 Level 1 Level 3 Level 1 Level 1 Level 1 Level 2
N10 Normal Level 5 Level 3 Level 5 Level 3 Level 1 Level 4 Level 4 Level 2 Level 3 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 5 Level 1 Level 4 Level 4 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 4
N11 Normal Level 4 Level 1 Level 4 Level 4 Level 1 Level 1 Level 4 Level 2 Level 2 Level 1 Level 1 Level 3 Level 1 Level 1 Level 3
(Continued to the next page)
Supplementary  Table 3 (Continued from the previous page) Results of LOH and MSP analyses on 100 patients
Tissue ID
Result of methylation-specific PCR
�
Type
MAGEA
2
TFF2 DDX53 MSLN
MASP-
IN
BGLAP MUC8
KIAA
1752
CDKN-
2A
ESR2 PPARG MLH1 CDH1 VDR RUNX31086 Y.-C. Jung, S.-J. Hong, Y.-H. Kim, et al.
Cancer Level 4 Level 2 Level 4 Level 4 Level 1 Level 2 Level 4 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 5
N12 Normal Level 5 Level 2 Level 4 Level 3 Level 1 Level 4 Level 4 Level 2 Level 3 Level 2 Level 1 Level 1 Level 1 Level 2 Level 4
Cancer Level 5 Level 2 Level 5 Level 4 Level 1 Level 3 Level 3 Level 3 Level 2 Level 1 Level 1 Level 1 Level 1 Level 2 Level 5
N13 Normal Level 5 Level 3 Level 5 Level 3 Level 1 Level 2 Level 5 Level 2 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 3 Level 5 Level 3 Level 1 Level 2 Level 4 Level 2 Level 1 Level 1 Level 1 Level 1 Level 1 Level 1 Level 4
N14 Normal Level 5 Level 1 Level 4 Level 3 Level 1 Level 1 Level 4 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 4 Level 1 Level 4 Level 5 Level 1 Level 2 Level 4 Level 1 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 5
N15 Normal Level 5 Level 3 Level 4 Level 4 Level 1 Level 2 Level 4 Level 2 Level 3 Level 1 Level 3 Level 1 Level 1 Level 1 Level 2
Cancer Level 5 Level 2 Level 4 Level 4 Level 2 Level 1 Level 4 Level 2 Level 2 Level 1 Level 3 Level 2 Level 2 Level 1 Level 2
N16 Normal Level 4 Level 2 Level 4 Level 3 Level 1 Level 1 Level 5 Level 2 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
Cancer Level 4 Level 4 Level 5 Level 5 Level 1 Level 2 Level 5 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 5
N17 Normal Level 5 Level 2 Level 4 Level 4 Level 1 Level 2 Level 5 Level 2 Level 1 Level 1 Level 2 Level 2 Level 1 Level 2 Level 2
Cancer Level 5 Level 3 Level 5 Level 4 Level 2 Level 1 Level 4 Level 3 Level 2 Level 1 Level 3 Level 2 Level 1 Level 2 Level 2
N18 Normal Level 5 Level 3 Level 5 Level 4 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 1 Level 2 Level 1 Level 2 Level 2
Cancer Level 4 Level 3 Level 4 Level 4 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 2 Level 2 Level 2 Level 2 Level 4
N19 Normal Level 5 Level 2 Level 4 Level 4 Level 2 Level 2 Level 5 Level 2 Level 3 Level 2 Level 3 Level 2 Level 1 Level 1 Level 2
Cancer Level 5 Level 2 Level 5 Level 5 Level 2 Level 1 Level 4 Level 2 Level 1 Level 1 Level 2 Level 2 Level 1 Level 1 Level 3
N20 Normal Level 5 Level 2 Level 5 Level 4 Level 1 Level 2 Level 5 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 5 Level 2 Level 5 Level 4 Level 2 Level 1 Level 5 Level 2 Level 1 Level 1 Level 2 Level 2 Level 2 Level 2 Level 4
N21 Normal Level 4 Level 2 Level 5 Level 2 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 3 Level 1 Level 1 Level 1 Level 3
Cancer Level 4 Level 1 Level 4 Level 3 Level 1 Level 2 Level 5 Level 3 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
N22 Normal Level 4 Level 2 Level 5 Level 3 Level 2 Level 2 Level 4 Level 2 Level 2 Level 2 Level 2 Level 2 Level 2 Level 1 Level 2
Cancer Level 4 Level 3 Level 4 Level 4 Level 2 Level 1 Level 4 Level 1 Level 2 Level 2 Level 2 Level 2 Level 2 Level 2 Level 2
N23 Normal Level 4 Level 3 Level 5 Level 3 Level 1 Level 1 Level 4 Level 2 Level 3 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 4 Level 3 Level 5 Level 5 Level 1 Level 2 Level 4 Level 2 Level 2 Level 2 Level 3 Level 1 Level 1 Level 1 Level 5
N24 Normal Level 4 Level 2 Level 4 Level 4 Level 1 Level 2 Level 4 Level 2 Level 2 Level 1 Level 2 Level 1 Level 1 Level 1 Level 3
Cancer Level 4 Level 2 Level 4 Level 4 Level 1 Level 2 Level 4 Level 2 Level 1 Level 2 Level 2 Level 1 Level 1 Level 1 Level 5
N25 Normal Level 4 Level 5 Level 5 Level 3 Level 1 Level 4 Level 5 Level 2 Level 1 Level 1 Level 2 Level 1 Level 1 Level 1 Level 2
Cancer Level 4 Level 5 Level 5 Level 3 Level 1 Level 4 Level 5 Level 2 Level 1 Level 1 Level 2 Level 2 Level 1 Level 2 Level 2
Supplementary  Table 3 (Continued from the previous page) Results of LOH and MSP analyses on 100 patients
Tissue ID
Result of methylation specific PCR
�
Type
MAGEA
2
TFF2 DDX53 MSLN
MASP-
IN
BGLAP MUC8
KIAA
1752
CDKN-
2A
ESR2 PPARG MLH1 CDH1 VDR RUNX3
*, LOH-H=high-level chromosomal losses, LOH-L=low-level chromosomal losses. 
� , Loss of single allele in the heterozygous case without MSI was
interpreted as a loss of heterozygosity (LOH+). 
�
, Proportion of the methylated CpGs was divided into 5 levels; level 1 (0-20% methylation), level 2 (21-
40% methylation), level 3 (41-60% methylation), level 4 (61-80% methylation), and level 5 (81-100% methylation).
LOH, loss of heterozygosity; MSP, methylayion-specific PCR.Genetic and Epigenetic Changes Related with Transcript Number in Gastric Cancer 1087
SAGE and EST libraries were downloaded from http://cgap.nci.nih.gov/.
Tissue No. Age Sex Information Library name
Embryo 1 SAGE_Embryonic_stem_cell_HES3_normal_p16_CL_ F Embryonic stem cell line - passage 16
SHE10
2 SAGE_Embryonic_stem_cell_HES4_normal_p36_CL_ M Embryonic stem cell line - passage 36
SHE11
Placenta 1 SAGE_Placenta_first_trimester_normal_B_1 First trimester placenta
2 SAGE_Placenta_normal_B_1 F Full-term placenta
Normal tissues
Stomach 1 SAGE_Stomach_normal_MD_13S M/F Male and Female, Microdissection
2 SAGE_Stomach_normal_epithelium_B_body1 Normal gastric epithelium, bulk
3 SAGE_Stomach_normal_B_antrum A pool of normal gastric epithelial tissues
obtained from the antrum
4 SAGE_Stomach_normal_MD_14S M/F Male and Female, Microdissection
Colon 1 SAGE_Colon_normal_B_NC1 Normal colonic epithelium
2 SAGE_Colon_normal_B_NC2 Normal colonic epithelium
Breast  1 SAGE_Breast_normal_epithelium_AP_Br_N 35 F Normal human luminal mammary epithelial
cells purified with BER-EP4 Ab.
2 SAGE_Breast_normal_epithelium_AP_1 43 F Normal human luminal mammary epithelial 
cells purified with BER-EP4 Ab.
3 SAGE_Breast_normal_myoepithelium_AP_IDC7 47 F Myoepithelial cells purified CD10 Ab.
4 SAGE_Breast_normal_stroma_AP_1 31 F Normal breast tissue
5 SAGE_Breast_normal_myoepithelium_AP_myoepithelial 27 F Myoepithelial cells purified CD10 Ab.
6 SAGE_Breast_normal_stroma_B_IDC8 44 F Normal breast tissue
Naso- 1 NCI_CGAP_HN11 Tongue, microdissected
pharynx 2 NCI_CGAP_HN19 Nasopharyngeal epithelium
3 NCI_CGAP_HN9 Retromolar trigone, microdissected
Cancer tissues
Stomach 1 SAGE_Stomach_adenocarcinoma_MD_HG7 71 F Adenocarcinoma, Microdissection
2 SAGE_Stomach_adenocarcinoma_MD_G329 60 Adenocarcinoma, Microdissection
3 SAGE_Stomach_adenocarcinoma_MD_HS29 66 F Adenocarcinoma, Microdissection
4 SAGE_Stomach_adenocarcinoma_B_G234 57 M Adenocarcinoma,,gastroesophageal 
junction, T4N0M0
5 SAGE_Stomach_carcinoma_B_xenograph_X43 78 F Poorly differentiated carcinoma, T4N1M0
6 SAGE_Stomach_carcinoma_B_G189 Poorly differentiated, T4N0M0
Colon 1 SAGE_Colon_adenocarcinoma_B_Tu102 Colon, primary tumor
2 SAGE_Colon_adenocarcinoma_B_Tu98 Colon, primary tumor
Breast 1 SAGE_Breast_carcinoma_B_95-259 56.5 F Invasive ductal carcinoma, ER-, PR-
2 SAGE_Breast_carcinoma_B_95-347 52.8 F Invasive ductal carcinoma, ER+, PR+
3 SAGE_Breast_carcinoma_B_BWHT18 44 F ER+, PR+, ErbB2 -
4 SAGE_Breast_carcinoma_B_IDC-4 F Invasive ductal carcinoma, ER-, ErbB2-, p53+
5 SAGE_Breast_carcinoma_B_IDC-5 F Invasive ductal carcinoma, ER+, ErbB2-, p53-
6 SAGE_Breast_metastatic_carcinoma_B_95-260 56.5 F Metastatic tumor. Paired with breast tumor
No. 2
7 SAGE_Breast_metastatic_carcinoma_B_95-348 52.8 F Metastatic tumor. Paired with breast tumor No. 3
8 SAGE_Breast_carcinoma_MD_LCIS 34 F Extensive LCIS
Naso- 1 NCI_CGAP_HN12 Tongue, microdissected
pharynx 2 NCI_CGAP_HN21 Nasopharyngeal carcinoma
3 NCI_CGAP_HN16 Retromolar trigone, microdissected
Supplementary  Table 4 List of SAGE and EST libraries used in analysis of transcript population1088 Y.-C. Jung, S.-J. Hong, Y.-H. Kim, et al.
Supplementary  Fig. 1. Schematic diagram of CpG islands and nearby retroelement distributions in the 5′ -end regions of 15 selected
genes. Of the six genes lacking CpG islands, the MAGEA2 and TFF2 genes have the L1 elements in a nearby 3-kb window, the DDX53
and MSLN genes have the Alu and L1 elements, and the MASPIN and BGLAP genes have the Alu elements. The remaining nine
genes contain CpG islands at the transcriptional start sites. The MUC8, KIAA1752, and CDKN2A genes were examined at the extra-
genic sites of the CpG-island margins close to the L1 elements, the ESR2 and PPARG2 genes were examined at those close to the
Alu and L1 elements, and the CDH1 gene was examined at those close to the Alu elements. The CpG islands of the MLH1, VDR,
and RUNX3 genes were bordered by the retroelements at a long distance. The MUC8 and KIAA1752 genes were examined at the
intragenic sites of the CpG island margins close to the L1 elements.
5′ to 3′
Symbols for retroelements
TFF2
DDX53
MSLN
MASPIN
BGLAP
MUC8
KIAA1752
CDKN2A
ESR2
PPARG
MLH1
CDH1
VDR
RUNX3
-10 kb -8 kb -6 kb -4 kb -2 kb TSS +2 kb +10 kb +8 kb +6 kb +4 kb
MAGEA2
Alu L1; TSS, transcription start site CpG island MSP primer siteGenetic and Epigenetic Changes Related with Transcript Number in Gastric Cancer 1089
Supplementary  Fig. 2. The methylation-variable CpGs of the TFF2, MSLN, BGLAP, CDKN2A, and MLH1 genes were analyzed by
cloning and sequencing the common PCR DNA. The CpG-island-negative genes (TFF2, MSLN, and BGLAP) showed both hypomethy-
lated and hypermethylated DNA strands in the transitional area or a methylation gradient between the hypomethylated proximal CpGs
and the hypermethylated distal CpGs. The CpG-island-positive genes (CDKN2A and MLH1) were unmethylated at the proximal CpG
site and methylated at the distal CpG site. The proportion of hypermethylated DNA strand was consistent with the level of methyla-
tion estimated by the intensity of methylation-specific PCR band.
Colon (C4) N
Methylation level 2
Stomach (S12) C
Stomach (S19) N Colon (C21) C
Breast (B2) N Stomach (S5) C
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Stomach (S12) N
Methylation level 3
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Breast (B1) C Stomach (S12) C
Stomach (S12) N Colon (C19) C
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Methylation level 4
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